Moody's Lowers Israel's Rating Citing Geopolitical Risks
By Stephen Nakrosis
Moody's Ratings downgraded Israel's credit ratings on Friday citing heightened geopolitical risks as the intensity of the country's fighting with Hezbollah has increased in recent days.
Israel's long-term local and foreign-currency issuer ratings were lowered to Baa1 from A2 and assigned a negative outlook.
The country's goal of returning evacuated residents back to its north will likely involve a more intense conflict, Moody's said, adding prospects for a ceasefire in Gaza have weakened and domestic political and geopolitical risks have risen.
Moody's also said it considers Israel's economy will be more durably weakened by the military conflict than previously expected. Given heightened security risks the swift and strong economic recovery that was seen after previous conflicts isn't expected.
Israel's real GDP is expected to grow 0.5% this year, Moody's said, and the company lowered expectations for growth next year to 1.5% from 4% previously.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 27, 2024 17:42 ET (21:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks